Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Sunshine Lake Pharma Co., Ltd.
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07082842CT.gov Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF | — | Recruiting | — | — | — |
NCT05060822CT.gov Phase ll Study of HEC585 in Patients With IPF | — | Active Not Recruiting | — | — | — |
NCT07588646CT.gov Study To Investigate The Potential DDI Between HEC585 And Pirfenidone/Nintedanib In Healthy Subjects | — | Completed | — | — | — |
NCT05383131CT.gov To Evaluate Drug-drug Interactions Between HEC585 and Pirfenidone or Nintedanib in Healthy Volunteers | — | Completed | — | — | — |
NCT04512170CT.gov Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC585 in Healthy Male and Female Subjects | — | Completed | — | — | — |
NCT03092102CT.gov The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Idiopathic Pulmonary Fibrosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| hec585 (this asset) | Sunshine Lake Pharma Co., Ltd. | P3 | B · 63 |
| Pirfenidone | Endeavor Biomedicines, Inc. | P4 | A |
| Acetylcysteine | Endeavor Biomedicines, Inc. | P4 | BBB |
| Nintedanib | Mannkind Corporation | P4 | BBB |
| Prednisone | Fondation Hôpital Saint-Joseph | P3 | BB |
| Nerandomilast | Boehringer Ingelheim | P3 | BB |
| hsk44459 | Haisco Pharmaceutical Group Co., Ltd. | P3 | BB |
| Sildenafil | Hoffmann-La Roche | P4 | BB |
| Bosentan | Actelion | P4 | B |
+42 more in the Idiopathic Pulmonary Fibrosis cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. hec585 in Idiopathic Pulmonary Fibrosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/hec585-idiopathic-pulmonary-fibrosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →